Eikon Therapeutics, Inc. Common Stock - Asset Resilience Ratio
Eikon Therapeutics, Inc. Common Stock (EIKN) has an Asset Resilience Ratio of 38.85% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how Eikon Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. See Eikon Therapeutics, Inc. Common Stock (EIKN) flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Eikon Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Eikon Therapeutics, Inc. Common Stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $231.07 Million | 38.85% |
| Total Liquid Assets | $231.07 Million | 38.85% |
Asset Resilience Insights
- Very High Liquidity: Eikon Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 38.85% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Eikon Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Eikon Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Genscript Biotech Corporation
F:G51 |
Biotechnology | 13.79% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
ZAI LAB LTD0000006
F:1ZLB |
Biotechnology | 0.91% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 34.30% |
Annual Asset Resilience Ratio for Eikon Therapeutics, Inc. Common Stock (2023–2025)
The table below shows the annual Asset Resilience Ratio data for Eikon Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 38.85% | $231.07 Million | $594.73 Million | +20.34pp |
| 2024-12-31 | 18.51% | $90.93 Million | $491.24 Million | -41.91pp |
| 2023-12-31 | 60.42% | $317.63 Million | $525.71 Million | -- |
About Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and… Read more